3-Amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases

Journal of Medicinal Chemistry

Volumn 51, Issue 5, 2008, Pages 1231-1241

  Ji, Zhiqin ^a   Ahmed, Asma A ^a   Albert, Daniel H ^a   Bouska, Jennifer J ^a   Bousquet, Peter F ^a   Cunha, George A ^a   Diaz, Gilbert ^a   Glaser, Keith B ^a   Guo, Jun ^a   Harris, Christopher M ^a   Li, Junling ^a   Marcotte, Patrick A ^a   Moskey, Maria D ^a   Oie, Tetsuro ^a   Pease, Lori ^a   Soni, Nirupama B ^a   Stewart, Kent D ^a   Davidsen, Steven K ^a   Michaelides, Michael R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTHIAZOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; UREA DERIVATIVE; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; DRUG EFFICACY; ENZYME INHIBITION; FIBROSARCOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BINDING SITES; BIOLOGICAL AVAILABILITY; CAPILLARY PERMEABILITY; CELL LINE; CELL LINE, TUMOR; EDEMA; FEMALE; HUMANS; ISOXAZOLES; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; NIH 3T3 CELLS; OXAZOLES; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; UTERUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 41649089003     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701096v     Document Type: Article

References (37)

1. Hubbard, S. R.; Till, J. H. Protein Tyrosine Kinases Structure and Function. Annu. Rev. Biochem. 2000, 69, 373-398.
2. Ullrich, A.; Schlessinger, J. Signal Transduction by Receptors with Tyrosine Kinase Activity. Cell 1990, 61, 203-212.
3. Strawn, L. M.; Shawver, L. K. Tyrosine Kinases in Disease: Overview of Kinase Inhibitors as Therapeutic Agents and Current Drugs in Clinical Trials. Expert Opin. Invest. Drugs 1998, 7, 553-573.
4. Bardelli, A.; Parsons, D. W.; Silliman, N.; Ptak, J.; Szabo, S.; Saha, S.; Markowitz, S.; Willson, J. K. V.; Parmigiani, G.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers. Science 2003, 300, 949-949.
5. Blume-Jensen, P.; Hunter, T. Oncogenic Kinase Signaling. Nature 2001, 411, 355-365.
6. Ferrara, N.; Gerber, H.-P.; LeCouter, J. The Biology of VEGF and Its Receptor. Nat. Med. 2003, 9, 669-676.
7. Shalaby, F.; Rossant, J.; Yamaguchi, T. P.; Gertsenstein, M.; Wu, X.-F.; Breitman, M. L.; Schuh, A. C. Failure of Blood-island Formation and Vasculogenesis in Flk-1-deficient Mice. Nature 1995, 376, 62-65.
8. Bilodeau, M. T.; Fraley, M. E.; Hartman, G. D. Kinases Insert Domain-Containing Receptor Kinase Inhibitors as Antiangiogenic Agents. Expert Opin. Invest. Drugs 2002, 11, 737-745.
9. Kim, I.; Kim, H. G.; Moon, S.-O.; Chae, S. W.; So, J.-N.; Koh, K. N.; Ahn, B. C.; Koh, G. Y. Angiopoietin-1 Induces Endothelial Cell Sprouting Through the Activation of Focal Adhesion Kinase and Plasmin Secretion. Circ. Res. 2000, 86, 952-959.
10. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J. Vascular-Specific Growth Factors and Blood Vessel Formation. Nature 2000, 407, 242-248.
11. Wang, D.; Huang, H.-J. S.; Kazlauskas, A.; Cavenee, W. K. Induction of Vascular Endothelial Growth Factor Expression in Endothelial Cells by Platelet-Derived Growth Factor Through the Activation of Phosphatidylinositol 3-Kinase. Cancer Res. 1999, 59, 1464-1472.
12. Lindahl, P.; Johansson, B. R.; Levéen, P.; Betsholtz, C. Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice. Science 1997, 277, 242-245.
13. Demetri, G. D. Targeting c-Kit Mutations in Solid Tumors: Scientific Rationale and Novel Therapeutic Options. Semin. Oncol. 2001, 28, 19-26.
14. Armstrong, S. A.; Kung, A. L.; Mabon, M. E.; Silverman, L. B.; Stam, R. W.; Den Boer, M. L.; Pieters, R.; Kersey, J. H.; Sallan, S. E.; Fletcher, J. A.; Golub, T. R.; Griffin, J. D.; Korsmeyer, S. J. Inhibition of FLT3 in MLL: Validation of a Therapeutic Target Identified by Gene Expression Based on Classification. Cancer Cell 2003, 3, 173-183.
15. Sawyers, C. L. Finding the Next Gleevec: FLT3 Targeted Kinase Inhibitor Therapy for Acute Myeloid Leukemia. Cancer Cell 2002, 1, 413-415.
16. Lux, M. L.; Rubin, B. P.; Biase, T. L.; Chen, C.-J.; Maclure, T.; Demetri, G.; Xiao, S.; Singer, S.; Fletcher, C. D. M.; Fletcher, J. A. KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors. Am. J. Pathol. 2002, 156, 791-5.
17. Stirewalt, D. L.; Radich, J. P. The Role of FLT3 in Haematopoietic Malignancies. Nat. Rev. Cancer 2003, 3, 650-665.
18. Banerji, L.; Sattler, M. Targeting Mutated Tyrosine Kinases in the Therapy of Myeloid Leukemias. Expert Opin. Ther. Targets 2004, 8, 221-239.
19. Eskens, F. Angiogenesis Inhibitors in Clinical Development; Where Are We Now and Where Are We Going. Br. J. Cancer 2004, 90, 1-7.
20. Gschwind, A.; Fisher, O. M.; Ullrich, A. The Discovery of Receptor Tyrosine Kinases: Targets for Cancer Therapy. Nat. Rev. Cancer 2004, 4, 361-370.
21. Vieth, M.; Sutherland, J. J.; Robertson, D. H.; Campbell, R. M. Kinomics: Characterizing the Therapeutically Validated Kinase Space. Drug Discovery Today 2005, 10, 839-846.
22. Fox, W. D.; Higgins, B.; Maiese, K. M.; Drobnjak, M.; Cordon-Cardo, C.; Scher, H. I.; Agus, D. B. Antibody to Vascular Endothelial Growth Factor Slows Growth of Androgen-independent Xenograft Model of Prostate Cancer. Clin. Cancer Res. 2001, 8, 3226-3231.
23. Stopeck, A.; Sheldon, M.; Vahedian, M.; Cropp, G.; Gosalia, R.; Hannah, A. Results of a Phase I Dode-Escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies. Clin. Cancer Res. 2002, 8, 2798-2805.
24. Bold, G.; Altmann, K.-H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Brüggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rösel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lässer, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
25. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rösel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schimer, M.; Thierauch, K.-H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F.; Marmé, D. PTK787/ZK222584, A Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration. Cancer Res. 2000, 60, 2178-2189.
26. Roberts, W. G.; Jani, J.; Beebe, J.; Emerson, E.; Gant, T.; Goodwin, P.; Higdon, C.; Hillerman, S.; Intrieri, C.; Knauth, E.; Marx, M.; Noe, M.; Rossi, A. M.; Savage, D.; Atherton, J.; Schaeffer, T.; Floyd, E.; Harriman, S. Preclincal Development of CP-547,632, a Novel VEGFR-2 Inhibitor for Cancer Therapy. Proceedings of the American Society of Clinical Oncology, 2002, Abstract #473.
27. Yoshiji, H.; Harris, S. R.; Thorgeirsson, U. P. Vascular Endothelial Growth Factor Is Essential for Initial But Not Continued In Vivo Growth of Human Breast Carcinoma Cells. Cancer Res. 1997, 57, 3924-3928.
28. Bergers, G.; Javaherian, K.; Lo, K. M.; Folkman, J.; Hanahan, D. Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice. Science 1999, 284, 808-812.
29. Carmeliet, P. Angiogenesis in Health and Disease. Nat. Med. 2003, 9, 653-660.
30. Mandel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In Vivo Antitumor Activity of SU11248, A Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Phamarcokinetic/Pharmacodynamic Relationship. Clin. Cancer Res. 2003, 9, 327-337.
31. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 2004, 64, 7099-7109.
32. Dai, Y.; Guo, Y.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Ahmed, A. A.; Albert, D. H.; Arnold, L.; Arries, S. S.; Barlozzari, T.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Pease, L. J.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Wishart, N.; Davidsen, S. K.; Michaelides, M. R. Thienopyrimidine Ureas as Novel Potent Multitargeted Receptor Tyrosine Kinases Inhibitors. J. Med. Chem. 2005, 48, 6066-6083.
33. Ji, Z.; Ahmed, A. A.; Albert, D. H.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Moskey, M.; D.; Pease, L. J.; Stewart, K. D.; Yates, M.; Davidsen, S. K.; Michaelides, M. R. Isothiazolopyrimidines and Isoxazolopyrimidines as Novel Multi-Targeted Inhibitors of Receptor Tyrosine Kinases. Bioorg. Med. Chem. Lett. 2006, 16, 4326-4330.
34. Heyman, H. R.; Frey, R. R.; Bousquet, P. F.; Cunha, G. A.; Moskey, M. D.; Ahmed, A. A.; Soni, N. B.; Marcotte, P. A.; Pease, L. J.; Glaser, K. B.; Yates, M.; Bouska, J. J.; Albert, D. H.; Black-Schaefer, C. L.; Dandliker, P. J.; Stewart, K. D.; Rafferty, P.; Davidsen, S. K.; Michaelides, M. R.; Curtin, M. L. Bioorg. Med. Chem. Lett. 2007, 17, 1246-1249.
35. Dai, Y.; Hartandi, K.; Ji, Z.; Ahmed, A. A.; Albert, D. H.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Harris, C. M.; Hickman, D.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Martin, R. L.; Olson, A. M.; Osterling, D. J.; Pease, L. J.; Soni, N. B.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Reuter, D. R.; Davidsen, S. K.; Michaelides, M. R. Discovery of N-(4-(3-Amino-1H-indazol-4-yl) phenyl)-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor. J. Med. Chem. 2007, 50, 1584-1597.
36. Albert, D. H.; Tapang, P.; Magoc, T. J.; Pease, L. J.; Reuter, D. R.; Wei, R.-Q.; Li, J.; Guo, J.; Bousquet, P. F.; Ghoreishi-Haack, N. S.; Wang, B.; Bukofzer, G. T.; Wang, Y.-C.; Stavropoulos, J. A.; Hartandi, K.; Niquette, A. L.; Soni, N.; Johnson, E. F.; McCall, J. O.; Bouska, J. J.; Luo, Y.; Donawho, C. K.; Dai, Y.; Marcotte, P. A.; Glaser, K. B.; Michaelides, M. R.; Davidsen, S. K. Preclinical Activity of ABT-869, A Multitargeted Receptor Tyrosine Kinase Inhibitor. Mol. Cancer Ther. 2006, 5, 995-1006.
37. 0-24 h) of 19.1 μM·hr.